The currently available antiviral substances (e.g., methisazone, idoxuridine, and amantadine hydrochloride) all have disadvantages such as limited spectrum of activity, limited therapeutic usefulness, or toxicity. Any new agent which would overcome any or all of these drawbacks would be of interest.
During the course of testing compounds for antiviral activity, one agent, 10-carboxymethyl-9-acridanone, was found to exert appreciable activity against Columbia SK, herpes, and coxsackie Bi virus infections in mice (R. I. Fryer and E. Grunberg, U.S. Patent 3,681,360, 1972) . The activity in these experimental infections, which was primarily prophylactic in nature, was sufficient and the spectrum broad enough to warrant further testing of this compound. Therefore experiments were undertaken to determine: (i) the effect against additional viruses, (ii) whether it was therapeutically as well as prophylactically active at doses below the toxic level, (iii) the mechanism of action, and (iv) the effect on humoral antibody synthesis. The results of these studies are described in the present communication.
MATERIALS AND METHODS
Compound description. 10-Carboxymethyl-9-acridanone sodium salt (CMA) is an odorless, yellow, crystalline solid whose melting point is >350 C. The substance is soluble in water (>1%) but not in acid and its molecular weight is 275.25. CMA has the structural formula shown in Fig. 1 .
Acute toxicity. The acute toxicity of CMA was determined in 18-to 20-g Royalhart mice by administering a single dose of the substance either intraperitoneally (i.p.), subcutaneously (s.c.), or orally (p.o.). All animals were observed for a period of 72 h, and the mean lethal dose (LD5,,) was calculated by the method of Reed and Muench (6) .
Virus infections in mice. Swiss albino mice (Royalhart) weighing 9 to 12 g (weanling) were infected i.p. with coxsackie A21, herpes simplex, pseudorabies, and Western equine encephalitis viruses, whereas intranasal instillation under light ether anesthesia was used to infect weanling mice with influenza A2/Asian/J305 
RESULTS
Acute toxicity. The LD-,,, values obtained after a single administration of CMA were: 1,516 mg/kg i.p., 3,031 mg/kg s.c., and >4,000 mg/kg p.o.
In vivo prophylactic activity. Appreciable activity was observed against Semliki forest, coxsackie Bi, herpes simplex, and pseudorabies virus infections in mice when CMA was administered i.p. at -24, 0, and 24 h relative to virus infection at 0 h (Table 1) . CMA was somewhat less active against Columbia SK virus. In the case of Western equine encephalitis virus, the PD50 was <100 mg/kg and the end point was not determined.
Utilizing the -24-, 0-, 24-h schedule and administering CMA s.c., a definite antiviral effect against Semliki forest and pseudorabies viruses was observed. Oral administration of CMA was also effective using the same treatment schedule, but considerably higher levels of CMA were necessary to obtain a 50% protection end point against Semliki forest and pseudorabies viruses.
In Table 2 are listed those viruses for which PD, values could not be obtained but against which CMA exerted a statistically significant effect (P 0.05) when the test substance was Contact inactivation. Incubation of Semliki forest or coxsackie Bi virus for 2 h at room temperature in the presence of 1,000 jig of CMA per ml did not significantly reduce the infectivity of these viruses in mice (Table 5) .
Humoral immune response. The effects of treatment with CMA on the humoral antibody response in mice administered either influenza virus or sheep erythrocytes are shown in Table  6 . Results obtained with a known immunosuppressive agent (methotrexate) are also listed for comparison. When CMA or methotrexate was administered to mice before immunization (3 the HI or HA titers of plasma irom drug-treated mice were essentially similar to those of watertreated mice. When CMA was administered after immunization (7 Post), the plasma HI or HA titers were not significantly different from those of the water-treated controls, whereas the Interferon-like activity. The results of testing pooled sera from mice given a single i.p. treatment with CMA or poly(rI:rC) for interferon-like activity are shown in Table 7 . When mouse sera were assayed in the homologous mouse L cells, interferon titers of both CMAtreated and poly(rI:rC)-treated animals were highest at 2 and 6 h and barely detectable at 24 h. The activity of both pools of sera was low when tested in the heterologous rabbit RK-13 cells.
Intravenous injection of 4,000 ,ug of CMA into rabbits failed to induce detectable levels of an interferon-like substance in the serum.
The protective effect resulting from incubation of mouse L cells or rabbit RK-13 cells with CMA or poly(rI:rC) before infection with vesicular stomatitis virus can be seen in Table 8 (1) (2) (3) (4) (5) 7) , and two of these substances, mepacrine and Acranil, have recently been described as inducers of an interferon-like substance in mice (1) .
The results of the present study indicate that CMA is prophylactically active (PD-,,) against both ribonucleic acid and deoxyribonucleic acid virus infections in mice at doses well below the toxic level when treatment is administered by the i.p., s.c., or p.o. route. Of particular importance is the observation that the substance also exerts a definite therapeutic effect in certain virus infections. CMA was shown to provide a definite protective effect when treatment was delayed for 2 h (Semliki forest), 6 h (Western equine encephalitis), 12 h (coxsackie Bi), or even 24 h (herpes simplex) after viral infection.
The activity found in mouse sera after i.p. administration of CMA has been described as interferon like. It appears to be species specific but, unlike poly(rI:rC), CMA does not induce an interferon-like substance in rabbits. Other characteristics normally associated with interferon need to be examined to more fully characterize this substance. It is possible that the antiviral effect noted with CMA is a composite of interferon-like activity and other, at present, undefined factors. The observation that CMA is therapeutically effective casts some doubt that interferon-like activity is the only explanation for its antiviral effect.
